Tianjin Chenxin Pharmaceutical Research

Tianjin Chenxin Pharmaceutical Research is a China-based biotechnology company focused on the research and development of innovative small molecule therapeutics. The company primarily targets metabolic diseases, with a significant emphasis on developing treatments for type 2 diabetes, including SGLT2 inhibitors and DPP-4 inhibitors. In addition to its internal drug discovery programs, the company provides contract research services to the broader pharmaceutical industry. Tianjin Chenxin operates out of the Tianjin Binhai New Area, leveraging local high-tech infrastructure to advance its clinical and preclinical candidates.